Literature DB >> 20872359

Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy.

Gaspare Monaco1, Viviana Cacioppo, Dario Consonni, Pasquale Troiano.   

Abstract

PURPOSE: To determine the effects of 2 artificial tear formulas on the ocular surface in patients with glaucoma using topical preserved beta-blockers (BB) or prostaglandins (PG).
METHODS: This was a prospective, comparative, randomized, double-blind study with a crossover design. Twenty patients with dry eye were divided into 2 groups based on glaucoma treatment: BB (10 subjects) or PG (10 subjects). Each group was administered a 4-week course of unpreserved isotonic (300 mOsm/L) solution containing 0.2% sodium hyaluronate (SH) or a preserved isotonic (295-305 mOsm/L) solution containing 0.5% carboxymethylcellulose and 0.9% glycerin as compatible solute (CMCs) administered QID. After a 2-week washout period, the course of treatment was reversed. The primary efficacy criteria consisted of assessing symptoms according to the Ocular Surface Disease Index© (OSDI); the secondary efficacy criteria consisted of evaluating tear film confocal microscopy, central corneal thickness (CCT), and lissamine corneal and conjunctival staining (Oxford Grading System Score [OGSS]).
RESULTS: Within each group, only CMCs induced a significant improvement in OSDI and OGSS compared to baseline values: OSDI -20.5, p<0.0001; OGSS -0.9, p<0.0001. Tear film confocal microscopy improved after treatment, especially in case of patients who were administered CMCs. No difference in CCT was noticed for any subject.
CONCLUSIONS: This study demonstrates for the first time that the use of concomitant CMCs in the management of glaucoma undergoing treatment with BB or PG may assist in tear film production and could lead to better compliance with intraocular pressure-lowering medication and ultimately better prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20872359     DOI: 10.5301/EJO.2010.5730

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

1.  Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders.

Authors:  Jack Stringham; Noy Ashkenazy; Anat Galor; Sarah R Wellik
Journal:  Eye Contact Lens       Date:  2018-01       Impact factor: 2.018

2.  Rasch analysis of the Ocular Surface Disease Index (OSDI).

Authors:  Bradley E Dougherty; Jason J Nichols; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

3.  Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial.

Authors:  Peter A Simmons; Haixia Liu; Cindy Carlisle-Wilcox; Joseph G Vehige
Journal:  Clin Ophthalmol       Date:  2015-04-15

4.  Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study.

Authors:  Pinnita Prabhasawat; Ngamkae Ruangvaravate; Nattaporn Tesavibul; Maneerat Thewthong
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-19       Impact factor: 2.671

5.  Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye.

Authors:  M Labetoulle; F Chiambaretta; A Shirlaw; R Leaback; C Baudouin
Journal:  Eye (Lond)       Date:  2017-04-28       Impact factor: 3.775

6.  Investigating the potential benefits of a new artificial tear formulation combining two polymers.

Authors:  Peter A Simmons; Joseph G Vehige
Journal:  Clin Ophthalmol       Date:  2017-09-12

7.  Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma.

Authors:  Ronald M Sánchez-Avila; Jesus Merayo-Lloves; Maria Laura Fernández; Luis Alberto Rodríguez-Gutiérrez; Pedro Pablo Rodríguez-Calvo; Andres Fernández-Vega Cueto; Francisco Muruzabal; Gorka Orive; Eduardo Anitua
Journal:  Int Med Case Rep J       Date:  2018-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.